Created in 2003, Medipol focuses on the life cycle management of biologics (biopharmaceuticals) and the revitalization of failed biologic compounds because of stability and delivery problems. Medipol’s goal is to become a biotech company improving pplication properties of biologics with world leading know-how and intellectual property for biopolymers and nanoparticle based technology. Medipol plans to build up a patent portfolio around the use of biopolymers as nanotechnology drug delivery.